CAN-FITE BIOPHARMA LTD. | ||
9/30/2013 | ||
Unaudited Pro Forma Interim Consolidated Balance Sheet | $1 = NIS 3.537 |
Convenience translation | ||||||||||||||||
Shares and | Into | |||||||||||||||
options issuance | Proforma data | U.S. dollars. | ||||||||||||||
September 30, | September 30, | September 30, | ||||||||||||||
2013 | 2013 | 2013 | ||||||||||||||
Unaudited | Unaudited | Unaudited | ||||||||||||||
NIS in thousands | NIS in thousands | NIS in thousands | In thousands | |||||||||||||
ASSETS | ||||||||||||||||
CURRENT ASSETS: | ||||||||||||||||
Cash and cash equivalents | 9,673 | 21,292 | 30,965 | 8,755 | ||||||||||||
Accounts receivable | 1,615 | 1,615 | 457 | |||||||||||||
11,288 | 21,292 | 32,580 | 9,211 | |||||||||||||
NON-CURRENT ASSETS: | ||||||||||||||||
Property, plant and equipment, net | 157 | 157 | 44 | |||||||||||||
11,445 | 21,292 | 32,737 | 9,256 | |||||||||||||
LIABILITIES AND EQUITY | ||||||||||||||||
CURRENT LIABILITIES: | ||||||||||||||||
Trade payables | 2,046 | 1,154 | 3,200 | 905 | ||||||||||||
Other accounts payable | 2,502 | 2,502 | 707 | |||||||||||||
Options exercisable into shares (series 6) | 149 | 149 | 42 | |||||||||||||
Options exercisable into shares (series 7) | 159 | 159 | 45 | |||||||||||||
Options exercisable into shares (series 8) | 308 | 308 | 87 | |||||||||||||
5,164 | 1,154 | 6,318 | 1,786 | |||||||||||||
NON-CURRENT LIABILITIES: | ||||||||||||||||
Options exercisable into shares (series 7) | - | - | ||||||||||||||
Employee benefit liabilities, net | 67 | 67 | 19 | |||||||||||||
5,231 | 1,154 | 6,385 | 1,805 | |||||||||||||
EQUITY (DEFICIENCY) ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: | ||||||||||||||||
Share capital | 3,568 | 459 | 4,027 | 1,139 | ||||||||||||
Share premium | 250,782 | 16,781 | 267,563 | 75,647 | ||||||||||||
Capital reserve from share-based payment transactions | 15,561 | 159 | 15,720 | 4,444 | ||||||||||||
Options exercisable into shares (series 9) | 669 | 669 | 189 | |||||||||||||
Options exercisable into shares (series 10) | 3,178 | 3,178 | 899 | |||||||||||||
Options exercisable into shares (series 11) | 3,066 | 3,066 | 867 | |||||||||||||
Options exercisable into shares (series 12) | 2,739 | 2,739 | 774 | |||||||||||||
Treasury shares | (3,628 | ) | (3,628 | ) | (1,026 | ) | ||||||||||
Adjustments arising from translating financial statements of foreign operations | (117 | ) | (117 | ) | (33 | ) | ||||||||||
Accumulated deficit | (269,371 | ) | (269,371 | ) | (76,158 | ) | ||||||||||
3,708 | 20,138 | 23,846 | 6,742 | |||||||||||||
Non-controlling interests | 2,506 | 2,506 | 709 | |||||||||||||
Total equity | 6,214 | 20,138 | 26,352 | 7,450 | ||||||||||||
11,445 | 21,292 | 32,737 | 9,256 |